The company reported that it has now also initiated the multiple ascending dose stage of the trial. The study is placebo-controlled, and the data remain blinded. Saniona continues to expect data ...

(Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced positive topline data from the Company’s single ascending dose (SAD) trial of VY7523 ...

March 03, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced positive topline data from the ...

(Nasdaq: TRDA) today announced it had received authorization from the United Kingdom’s Medicines and Healthcare Products Regulatory Agency (MHRA) and Research Ethics Committee for its Clinical Trial ...

a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, announced that the first CF and OTC ...

Arcturus Therapeutics (ARCT) Holdings announced that the first CF and OTC deficiency participants initiated dosing in December 2024, in the company’s Phase 2 multiple ascending dose studies.

The multiple-ascending dose portion is planned to enroll two cohorts, each receiving subcutaneous injections of DISC-3405. Following completion of this study, Disc plans to initiate a trial in ...

Single ascending doses to be evaluated in healthy volunteers in Q4 2022 Single ascending doses to be evaluated in subjects with chronic hepatitis B beginning in Q1 2023 SOUTH SAN FRANCISCO ...

Up to 53 patients to be enrolled in open-label study across multiple sites in Australia, Hong Kong and South Korea Special Report: Race Oncology has initiated its lead trial site Southside Cancer ...